Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Other Accumulated Expenses (2022 - 2026)

Immuneering's Other Accumulated Expenses history spans 5 years, with the latest figure at $44191.0 for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses fell 21.83% to $44191.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $44191.0, a 21.83% decrease, with the full-year FY2025 number at $291513.0, up 24.76% from a year prior.
  • Other Accumulated Expenses came in at $44191.0 for Q1 2026, down from $291513.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $291513.0 in Q4 2025, with the low at $19796.0 in Q4 2022.
  • Historically, Other Accumulated Expenses has averaged $96526.3 across 5 years, with a median of $56531.0 in 2025.
  • Peak annual rise in Other Accumulated Expenses hit 1212.23% in 2023, while the deepest fall reached 44.23% in 2023.
  • Year by year, Other Accumulated Expenses stood at $19796.0 in 2022, then soared by 1212.23% to $259770.0 in 2023, then decreased by 10.05% to $233665.0 in 2024, then rose by 24.76% to $291513.0 in 2025, then plummeted by 84.84% to $44191.0 in 2026.
  • Business Quant data shows Other Accumulated Expenses for IMRX at $44191.0 in Q1 2026, $291513.0 in Q4 2025, and $80089.0 in Q3 2025.